AMR Bio

AMR Bio is a clinical-phase biotechnology company advancing XF-73, a Phase III-ready topical antimicrobial using an ultra-rapid antibacterial mechanism to prevent post-surgical staphylococcal infections, including MRSA.

The company was formed to carry forward intellectual property and clinical assets acquired from Destiny Pharma, aiming to progress the programme toward commercialisation.

AMR Bio's work addresses antimicrobial resistance, a growing public health challenge as existing antibiotics become less effective against drug-resistant infections.